Related Experiment Video
Updated: Jul 5, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Trans-sodium crocetinate for treating hypoxia/ischemia.
1Diffusion Pharmaceuticals LLC, 2020 Avon Court, #4, Charlottesville, VA 22902, USA. jgainer@diffusionpharma.com
Trans-sodium crocetinate (TSC) enhances oxygen diffusion to treat hypoxia and ischemia. This novel compound is safe for human use and shows promise for conditions like hemorrhagic shock.
Area of Science:
- Biochemistry
- Pharmacology
Background:
- Trans-sodium crocetinate (TSC) is a novel therapeutic agent.
- Originally developed for hemorrhagic shock, TSC has demonstrated safety in preclinical and Phase I human trials.
Purpose of the Study:
- To investigate the mechanism of action of TSC.
- To evaluate TSC's potential for treating hypoxia and ischemia.
Main Methods:
- Investigated the effect of TSC on water structure in blood plasma.
- Examined the impact of TSC on oxygen diffusion rates between erythrocytes and tissues.
Main Results:
- TSC alters blood plasma water structure by promoting hydrogen bonds.
- This alteration enhances the rate of oxygen diffusion, potentially improving tissue oxygenation.
Conclusions:
- TSC's unique mechanism offers a novel therapeutic approach.
- Further development is underway for applications in hemorrhagic shock and other ischemic conditions.
More Related Videos
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
10:13Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017